- Rank in Search Criteria: 4551
World Rank (Jan-05-2024): 15,418
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 15517
Market Cap (Jul-30-2023): 0.32 Billion USD
World Rank (Jan-2022): 14,748
Market Cap (Jan-2022): 0.41 Billion USDHeadquarters Country: USA Annual Revenue in USD: 29 Million USD
Annual Net Income in USD: 28 Million USD
Annual Results for Period ending: Oct-2020 ending year
- Rank in Search Criteria: 4552
World Rank (Jan-05-2024): 15,422
World Rank (Jul-30-2023): 15422
Market Cap (Jul-30-2023): 0.32 Billion USD
World Rank (Jan-2022): 15,734
Market Cap (Jan-2022): 0.35 Billion USDHeadquarters Country: USA Annual Revenue in USD: 3,233 Million USD
Annual Net Income in USD: 411 Million USD
Annual Results for Period ending: Dec-2019 ending yearEmployee Count: 9,227
Employee Count as of Date: As on 2021
- Rank in Search Criteria: 4553
World Rank (Jan-05-2024): 15,425
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 15719
Market Cap (Jul-30-2023): 0.31 Billion USD
World Rank (Jan-2022): 15,189
Market Cap (Jan-2022): 0.38 Billion USD
- Rank in Search Criteria: 4554
World Rank (Jan-05-2024): 15,429
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 14889
Market Cap (Jul-30-2023): 0.36 Billion USD
World Rank (Jan-2022): 17,088
Market Cap (Jan-2022): 0.28 Billion USD
- Rank in Search Criteria: 4555
World Rank (Jan-05-2024): 15,435
World Rank (Jul-30-2023): 15435
Market Cap (Jul-30-2023): 0.32 Billion USD
World Rank (Jan-2022): 12,942
Market Cap (Jan-2022): 0.54 Billion USDHeadquarters Country: USA Annual Revenue in USD: 626 Million USD
Annual Net Income in USD: -8 Million USD
Annual Results for Period ending: Dec-2021 ending yearCompany Profile: Sculptor Capital Management is an Alternative Asset Manager Providing a range of products across Multi Strategy, Credit and Real Estate company. The company annual revenue is 112 million USD and more than 350 employees as on 2019. The headquarters is in USA.
- Rank in Search Criteria: 4556
World Rank (Jan-05-2024): 15,443
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 16282
Market Cap (Jul-30-2023): 0.28 Billion USD
Headquarters Country: USA
- Rank in Search Criteria: 4557
World Rank (Jan-05-2024): 15,445
World Rank (Jul-30-2023): 15445
World Rank (Jan-2022): 15,445
Headquarters Country: USA Annual Revenue in USD: 777 Million USD
Annual Net Income in USD: -73 Million USD
Annual Results for Period ending: Dec-2020 ending period
- Rank in Search Criteria: 4558
World Rank (Jan-05-2024): 15,452
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 15724
Market Cap (Jul-30-2023): 0.31 Billion USD
World Rank (Jan-2022): 14,451
Market Cap (Jan-2022): 0.43 Billion USDHeadquarters Country: USA
- Rank in Search Criteria: 4559
World Rank (Jan-05-2024): 15,460
Market Cap (Jan-05-2024): 0.32 Billion USD
World Rank (Jul-30-2023): 21173
Market Cap (Jul-30-2023): 0.11 Billion USD
World Rank (Jan-2022): 16,210
Market Cap (Jan-2022): 0.32 Billion USDHeadquarters Country: USA Annual Revenue in USD: 10 Million USD
Annual Net Income in USD: -37 Million USD
Annual Results for Period ending: Dec-2020 ending yearEmployee Count: 48
Employee Count as of Date: As of 2020
Company Profile: Shattuck Labs is a fully Integrated Biotechnology company that creates novel therapeutics for the treatment of cancer and autoimmune disease. The company annual revenue is 9.89 million USD and 45 employees as on 2019. The headquarters is in USA.
- Rank in Search Criteria: 4560
World Rank (Jan-05-2024): 15,475
World Rank (Jul-30-2023): 15475
World Rank (Jan-2022): 15,475
Market Cap (Jan-2022): 0.36 Billion USDHeadquarters Country: USA Annual Revenue in USD: 0 Million USD
Annual Net Income in USD: -77 Million USD
Annual Results for Period ending: Dec-2020 ending yearEmployee Count: 55
Employee Count as of Date: As on 2021
Company Profile: Cortexyme is a Clinical Stage Biopharmaceutical company. It is a pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed and other degenerative diseases. The company is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. The headquarters is in USA.